Wells Fargo’s Mustang Bio MBIO Stock Holding History

Wells Fargo’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7	Closed	-$13K	–	7579
2021 Q3	$13K	Buy	+7	New	+$15K	﹤0.01%	6121

Other funds holding MBIO

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo's MBIO Position: Q2 2025 in Review

Wells Fargo sold out of Mustang Bio (MBIO) in Q2 2025, closing a stake of 400 shares — an estimated $500 sold.

Wells Fargo first reported a position in MBIO in Q4 2017 and held it in 30 quarters. The position peaked at $335K in Q4 2020. 17 funds tracked by Wall St. Rank hold MBIO as of Q2 2025.

Wells Fargo reported no remaining Mustang Bio position as of Q2 2025 after selling out during the quarter.
Wells Fargo sold 400 Mustang Bio shares in Q2 2025, an estimated $500.
Wells Fargo first reported a position in Mustang Bio in Q4 2017 and held it in 30 quarters.
Wells Fargo's Mustang Bio position peaked at $335K in Q4 2020.
17 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2025.

Based on Wells Fargo's 13F filing for Q2 2025, filed 14 Aug 2025.